Research graph
References from The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1126/science.aar4060
10.1126/science.aar4060 · External reference
10.1126/science.aar6711
10.1126/science.aar6711 · External reference
10.1038/s12276-018-0191-1
10.1038/s12276-018-0191-1 · External reference
10.1158/1535-7163.mct-17-0386
10.1158/1535-7163.mct-17-0386 · External reference
10.1158/2159-8290.cd-14-1397
10.1158/2159-8290.cd-14-1397 · External reference
10.1158/1535-7163.mct-14-0983
10.1158/1535-7163.mct-14-0983 · External reference
10.1038/s41392-020-00449-4
10.1038/s41392-020-00449-4 · External reference
10.1016/j.cell.2017.08.031
10.1016/j.cell.2017.08.031 · External reference
10.1016/j.annonc.2021.02.006
10.1016/j.annonc.2021.02.006 · External reference
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
10.1186/s40425-019-0768-9 · 2019 · External reference
Cancer type-dependent correlations between TP53 mutations and antitumor immunity
2020 · External reference
ARID1A mutations correlate with increased immune activity in gastrointestinal cancer
10.3390/cells8070678 · 2019 · External reference
KALRN mutations promote antitumor immunity and immunotherapy response in cancer
2020 · External reference
10.1158/1078-0432.ccr-16-2554
10.1158/1078-0432.ccr-16-2554 · External reference
10.1016/j.csbj.2019.07.009 · Admitted local publication
10.1016/j.ebiom.2019.03.068
10.1016/j.ebiom.2019.03.068 · External reference
Cell cycle activity correlates with increased anti-tumor immunity in diverse cancers
2020 · External reference
10.3390/cells10040923
10.3390/cells10040923 · External reference
The spliceosome as target for anticancer treatment
10.1038/sj.bjc.6604801 · 2009 · External reference
10.1016/j.ccell.2018.07.001
10.1016/j.ccell.2018.07.001 · External reference
10.1016/j.celrep.2018.03.052
10.1016/j.celrep.2018.03.052 · External reference
10.1016/j.cell.2020.12.031
10.1016/j.cell.2020.12.031 · External reference
10.1093/bioinformatics/bts452
10.1093/bioinformatics/bts452 · External reference
10.1093/nar/gky973
10.1093/nar/gky973 · External reference
10.1007/s12094-018-1968-3
10.1007/s12094-018-1968-3 · External reference
10.1056/nejmoa1406498
10.1056/nejmoa1406498 · External reference
10.1158/2326-6066.cir-16-0019
10.1158/2326-6066.cir-16-0019 · External reference
Unresolved reference
External reference
10.1371/journal.pmed.1002309
10.1371/journal.pmed.1002309 · External reference
10.1186/1471-2105-14-7
10.1186/1471-2105-14-7 · External reference
An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles
10.1038/s42003-020-01230-7 · 2020 · External reference
10.1073/pnas.1818210116
10.1073/pnas.1818210116 · External reference
10.1093/nar/gkw1092
10.1093/nar/gkw1092 · External reference
10.1038/nrclinonc.2018.27
10.1038/nrclinonc.2018.27 · External reference
10.1111/j.2517-6161.1995.tb02031.x
10.1111/j.2517-6161.1995.tb02031.x · External reference
10.1038/ncomms3612
10.1038/ncomms3612 · External reference
10.1016/j.celrep.2018.03.076
10.1016/j.celrep.2018.03.076 · External reference
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
10.1097/md.0000000000004766 · 2016 · External reference
10.3390/biom5042935
10.3390/biom5042935 · External reference
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
10.1126/science.aaf8399 · 2017 · External reference
10.1016/j.jtcvs.2017.06.062
10.1016/j.jtcvs.2017.06.062 · External reference
10.1080/17476348.2020.1746646
10.1080/17476348.2020.1746646 · External reference
Clinicopathologic features and prognosis of BRAF mutated colorectal cancer patients
10.3389/fonc.2020.563407 · 2020 · External reference
10.1210/jc.2005-0987
10.1210/jc.2005-0987 · External reference
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
10.1186/s12885-017-3529-5 · 2017 · External reference
Molecular targeting and immunomodulatory actions
10.3390/cancers12071823 · 2020 · External reference
10.3389/fonc.2019.01088
10.3389/fonc.2019.01088 · External reference
10.1210/me.2010-0164
10.1210/me.2010-0164 · External reference
10.1016/j.ctrv.2019.101896
10.1016/j.ctrv.2019.101896 · External reference
10.1074/jbc.m501725200
10.1074/jbc.m501725200 · External reference
10.7554/elife.07938
10.7554/elife.07938 · External reference
10.1097/jcma.0000000000000251
10.1097/jcma.0000000000000251 · External reference
RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent
10.1186/s13046-021-01871-4 · 2021 · External reference
10.1016/j.tibs.2006.04.003
10.1016/j.tibs.2006.04.003 · External reference
10.1186/s13046-015-0239-1
10.1186/s13046-015-0239-1 · External reference
10.1158/0008-5472.can-12-2014
10.1158/0008-5472.can-12-2014 · External reference
10.1038/modpathol.2012.161
10.1038/modpathol.2012.161 · External reference
p53 in the DNA-damage-repair process
10.1101/cshperspect.a026070 · 2016 · External reference
Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy
10.1158/0008-5472.can-12-2501 · 2013 · External reference
10.1093/nar/gkab452
10.1093/nar/gkab452 · External reference
10.1016/j.cell.2004.07.013
10.1016/j.cell.2004.07.013 · External reference
10.1016/j.cell.2017.06.010
10.1016/j.cell.2017.06.010 · External reference
10.1073/pnas.0506580102
10.1073/pnas.0506580102 · External reference
10.1002/0471142905.hg1116s87
10.1002/0471142905.hg1116s87 · External reference
Correlate tumor mutation burden with immune signatures in human cancers
10.1186/s12865-018-0285-5 · 2019 · External reference
10.1056/nejmoa1500596
10.1056/nejmoa1500596 · External reference
